Research · 10 min read
What a National Drug Code Identifies, and What It Does Not
The number on a drug package is three numbers in a row, and each one answers a different question. The regulation that creates it also says plainly that having one is not approval of anything.
Key takeaways
- The code identifies three things: the labeler, the product, and the package size and type.
- It is 10 or 11 digits in three segments, and only certain segment-length combinations are permitted.
- A company with a given labeler code must use one product-package configuration across every code it holds.
- A labeler code is applied for and its contact information must be updated within 30 calendar days of any change.
- A code can be reserved before a product is listed, for two years, after which the reservation lapses.
- Changes to name, active ingredient, strength, dosage form, prescription status, human or animal use, or distinguishing characteristics require a new product code.
- Using a code to denote or imply approval, or on a product outside the listing parts such as a dietary supplement, is named as a basis for a misbranding finding.
- The regulation states that assignment of a code, inclusion in the database, and establishment registration do not denote approval or legal marketability.
- Registration and listing may still be evidence that a facility does drug operations or that a product is intended to be a drug.
- Registration information and post-marketing listing information are public by default, with three named categories withheld.
Answer first: three segments, three different facts
The regulation defines the code and then says exactly what it is for.
The code for a drug is a numeric code. Each finished drug product or unfinished drug subject to the listing requirements must have a unique code to identify its labeler, product, and package size and type.
Read that as three questions with three answers. Who is putting their name on it, which product it is, and which package of that product you are holding.
The format follows. Except for one narrow exception, the code must consist of 10 or 11 digits divided into three segments.
The first segment is the labeler code, consisting of 4, 5 or 6 digits, and it is assigned by the agency. The second is the product code, 3 or 4 digits. The third is the package code, 1 or 2 digits.
The package segment does more work than people expect. It identifies the package size and type, and differentiates between different quantitative and qualitative attributes of the product packaging.
Why the same code appears in two different lengths
Anyone comparing a carton to a database entry runs into this, and the regulation explains it.
The permissible combinations are listed. A labeler code of 5 or 6 digits may be combined in two ways. Either with a 4-digit product code and a 1-digit package code, or with a 3-digit product code and a 2-digit package code, for a total of 10 or 11 digits.
A 4-digit labeler code may be combined only with a 4-digit product code and a 2-digit package code, for a total of 10 digits.
One rule keeps a single company internally consistent. A registrant or private label distributor with a given labeler code must use only one product-package code configuration, and that single configuration must be used in all codes containing that labeler code.
So the segment lengths are not arbitrary and they are not free-floating. Once a company's configuration is set, every code it holds follows the same shape.
Who has to get one, and how a number gets attached to a product
The code is applied for, then proposed, then assigned, and those are three distinct steps.
Each person who engages in manufacturing, repacking, relabeling or private label distribution of a drug subject to listing must apply for a labeler code.
The application asks for the name, physical address, email address and other contact information of the person the code is for. It also asks for the types of activities that person engages in with respect to human drugs, and the types of drugs the code will be applied to.
Once assigned, that information has to be kept current. It must be updated within 30 calendar days after any change.
A specific code is proposed for assignment when it is first submitted with listing information. Each manufacturer, repacker or relabeler must propose a code including its own labeler code for each package size and type it handles for commercial distribution.
Private label products get a second one. Say a drug is distributed under the trade name or label of a private label distributor. The manufacturer, repacker or relabeler must also propose a code containing that distributor's labeler code, for each package size and type so distributed.
Assignment happens on receipt of listing information, provided the proposed code conforms and is not reserved for or previously assigned to a different drug.
A number can be held before a product exists
One provision explains a code that appears in a database with nothing behind it yet.
A manufacturer, repacker, relabeler or private label distributor may voluntarily reserve a proposed code for a drug before the drug is listed.
Reserving one requires three things: a proposed code that conforms to the format, the established name and strength of each active ingredient, and for a finished drug product the dosage form and route of administration.
The reservation is time-limited. If the required information is submitted and the code is properly formatted and not already assigned or reserved, it is reserved for a period of two years from the date of submission.
And it expires by itself. If the drug is not listed during that two-year period, the reservation lapses. It can also be cancelled at any time on request of the person whose labeler code it contains.
So a reserved code is a placeholder with a clock on it, not evidence that a product is being made.
What changes force a new number
The code is not a permanent name for a family of products, and the list of triggers is specific.
Once a code has been assigned, a new and unique one must be proposed when there is a change, after initial marketing, to certain information.
A new product code is required for a change to the drug's established name or proprietary name. The same is true for a change to any active pharmaceutical ingredient or its strength, to the dosage form, or to the drug's status between prescription and nonprescription.
It is also required for a change in intended use between human and animal, and for a change in distinguishing characteristics such as size, shape, color, code imprint, flavor and scoring.
Packaging alone is handled more gently. Where the only change is to package size or type, including the immediate unit-of-use container, the new code takes only a new package code. It keeps the existing product code, unless every available package code has already been used with it.
One direction of travel is fixed. If marketing resumes for a discontinued drug and nothing has changed that would require a new code, the drug must carry the same code it had before marketing stopped.
Three ways using a code is a violation
The restrictions section is short and each item describes something a reader might actually see.
A product may be deemed to be misbranded if a code is used to represent a different drug than the one it was assigned for.
It may be deemed misbranded if a code is used to denote or imply approval of a drug.
And it may be deemed misbranded if a code is used on products that are not subject to the drug, blood or tissue listing parts. The regulation names dietary supplements and medical devices as examples.
That third one is worth holding onto in a category full of supplements presented alongside medications. A code-shaped number printed on a supplement is not a drug identifier borrowed for convenience; the regulation names that use as a basis for a misbranding finding.
What a code and a database entry do not certify
The regulation devotes an entire section to this, and it is unusually direct.
Registration of an establishment or listing of a drug does not denote approval of the establishment, the drug, or the establishment's other drugs, nor does it mean that a product may be legally marketed.
It then names the misuse. Any representation that creates an impression of official approval, or that a drug is approved or legally marketable because of registration or listing, is misleading and constitutes misbranding.
A second paragraph extends that to the code itself and to the database. Acceptance of registration and listing information does not denote approval of the establishment or the drug. Neither does inclusion of a drug in the agency's database, nor assignment of a code, and none of them means the drug may be legally marketed.
The same misbranding sentence follows, and it names four specific claims. That a drug is approved or legally marketable because it appears in the database. Because it has been assigned a code. Because it displays a code. Or because the establishment has been assigned a registration number or unique facility identifier.
A third paragraph draws a line in the other direction. Neither registration nor listing constitutes a determination that a product is a drug. But registration or listing may be evidence that a facility intends to or does manufacture, repack, relabel, distribute or salvage drugs, or that a product is intended to be a drug.
What is public and what is held back
The disclosure section explains why a database entry answers some questions and not others.
The default is release. All establishment registration information is available for public disclosure, and after a drug is marketed, the information obtained under the code, listing and updating sections is too.
Three categories are withheld unless already public or unless confidentiality would be inconsistent with protecting the public health.
Information submitted as the basis for a determination that a particular drug is not subject to the new drug or biologics provisions.
The names of inactive ingredients for which the registrant makes a valid assertion of confidentiality under the agency's trade secret and confidential information rules.
And listing information obtained under the reservation provision and several specific listing paragraphs.
The agency also reserves a case-by-case exemption, in limited circumstances, where withholding would be consistent with public health protection and the federal disclosure statute.
What the whole system is for
The purpose section states it in two sentences and they are worth reading before drawing conclusions from a code.
Establishment registration information helps the agency identify who is manufacturing, repacking, relabeling and salvaging drugs, and where those operations are performed.
Drug listing information gives the agency a current inventory of drugs manufactured, repacked, relabeled or salvaged for commercial distribution.
Both types facilitate implementation and enforcement of the statute and are used for many important public health purposes.
That is an inventory and an address book. It is a good answer to who and where, and it is not an answer to whether anything was reviewed.
What to do with a number you are shown
Four checkable moves come out of the above.
Count the digits and the segments. Ten or eleven digits in three parts is the shape the regulation describes; anything else is not a code in that format.
Ask which of the three segments the seller is relying on. A shared labeler code across two products says something about who labels them and nothing about what they contain.
Ask what the product it names actually is. A change of active ingredient, strength, dosage form or prescription status requires a new product code, so a code carried across such a change does not describe what is in the package now.
And do not read approval into it. The regulation says assignment of a code does not denote approval and that claiming otherwise is misbranding.
What this page does not tell you
Three boundaries, stated where you can see them.
Everything above is drawn from the text of the federal registration, listing and code regulation. No product is checked, no company is named, and nothing here says whether any particular use of a code is compliant.
The code section carries a note pointing to an amendment published in the Federal Register in March 2026. That amendment document was not read and nothing here describes what it changes. Anyone relying on the format details should check that notice.
And the marketing phrase about being registered with the agency has its own separate treatment, which is not repeated here. What is above is about the number itself.
Sources
- 21 CFR Part 207 — Requirements for Foreign and Domestic Establishment Registration and Listing for Human Drugs, and the National Drug CodeSection 207.5 for the stated purpose — establishment registration information helping identify who is manufacturing, repacking, relabeling and salvaging drugs and where those operations are performed; drug listing information giving a current inventory of drugs manufactured, repacked, relabeled or salvaged for commercial distribution; and both facilitating implementation and enforcement and being used for many important public health purposes. Section 207.33(a) for the code being a numeric code and each finished drug product or unfinished drug subject to listing having a unique code identifying its labeler, product, and package size and type; 207.33(b)(1) for the 10 or 11 digits in three segments, the labeler code of 4, 5 or 6 digits assigned by FDA, the product code of 3 or 4 digits, and the package code of 1 or 2 digits identifying package size and type and differentiating quantitative and qualitative packaging attributes; 207.33(b)(2)(i) and (ii) for the permissible combinations; 207.33(b)(3) for a registrant or private label distributor with a given labeler code using only one product-package code configuration across all its codes; 207.33(c)(1) for who must apply for a labeler code and the three items required; 207.33(c)(2) for updating that information within 30 calendar days of any change; 207.33(d)(1) for a code being proposed when first submitted with listing information, (d)(1)(i) for each manufacturer, repacker or relabeler proposing a code with its own labeler code for each package size and type, and (d)(1)(ii) for the additional code containing a private label distributor's labeler code; 207.33(d)(2) for assignment on receipt of listing information where the proposed code conforms and is not reserved for or previously assigned to a different drug; 207.33(d)(3) for voluntary reservation and the three items required; 207.33(d)(4) for the two-year reservation from the date of submission, its lapse if the drug is not listed, and cancellation on request. Section 207.35(a) for proposing a new and unique code on a change after initial marketing; 207.35(b)(1) through (6) for the six changes requiring a new product code; 207.35(c) for a package-only change taking a new package code and retaining the existing product code unless all available package codes have been used. Section 207.37(a)(1) through (3) for the three uses that may render a product misbranded, including use to denote or imply FDA approval and use on products not subject to the listing parts such as dietary supplements and medical devices; 207.37(b) for a resumed discontinued drug keeping its prior code where no change requiring a new one has occurred. Section 207.77(a) for registration or listing not denoting approval of the establishment, the drug or other drugs of the establishment, nor meaning a product may be legally marketed, and for any representation creating an impression of official approval being misleading and constituting misbranding; 207.77(b) for the same being true of FDA's acceptance of registration and listing information, inclusion in the database of drugs, and assignment of a code, and for the four specific claims named as misleading; 207.77(c) for neither registration nor listing constituting a determination that a product is a drug, while being possible evidence of intent or of drug operations. Section 207.81(a) for the default public disclosure of all establishment registration information and, after a drug is marketed, information obtained under the code, listing and updating sections; 207.81(b)(1) through (3) for the three withheld categories; 207.81(c) for the limited case-by-case exemption.
Frequently asked questions
What do the three parts of a National Drug Code mean?
The regulation says the code identifies its labeler, product, and package size and type. The first segment is the labeler code, 4, 5 or 6 digits, assigned by the agency. The second is the product code, 3 or 4 digits. The third is the package code, 1 or 2 digits, which identifies package size and type and differentiates between different quantitative and qualitative attributes of the packaging.
Why do I see the same code written with 10 digits and 11?
Because the permissible segment lengths vary. A 5- or 6-digit labeler code can pair with a 4-digit product code and 1-digit package code, or with a 3-digit product code and 2-digit package code, giving a 10- or 11-digit total. A 4-digit labeler code may pair only with a 4-digit product code and a 2-digit package code, for 10 digits. A company with a given labeler code must use only one product-package configuration across all its codes.
Does having a code mean FDA approved the drug?
No, and the regulation says so twice. Registration or listing does not denote approval of the establishment, the drug or the establishment's other drugs, nor mean a product may be legally marketed. Acceptance of registration and listing information, inclusion in the agency's database, or assignment of a code likewise does not. Any representation creating the impression that a drug is approved or legally marketable is misleading and constitutes misbranding. That covers claims resting on its appearing in the database, on its having been assigned or displaying a code, or on the establishment having a registration number or unique facility identifier.
Can a dietary supplement carry one?
The regulation lists that as a basis for a misbranding finding. A product may be deemed misbranded if a code is used on products that are not subject to the drug, blood or tissue listing parts. The regulation names dietary supplements and medical devices as examples of such products.
What changes require a new code?
A new product code is required for several changes made after initial marketing. A change to the drug's established or proprietary name, to any active pharmaceutical ingredient or its strength, or to the dosage form. A change to prescription or nonprescription status, or to intended use between human and animal. Or a change to distinguishing characteristics such as size, shape, color, code imprint, flavor and scoring. A change only to package size or type takes a new package code while keeping the existing product code, unless every available package code has already been used with it.
Can a company hold a code before it has a product?
Yes, temporarily. A manufacturer, repacker, relabeler or private label distributor may voluntarily reserve a proposed code before the drug is listed. That takes three things: a conforming code, the established name and strength of each active ingredient, and for a finished product the dosage form and route of administration. The reservation lasts two years from the date of submission and lapses if the drug is not listed in that time.
Why does one product sometimes have two codes?
Private label distribution. Each manufacturer, repacker or relabeler proposes a code containing its own labeler code for each package size and type it handles. Say the drug is also distributed under the trade name or label of a private label distributor. That manufacturer, repacker or relabeler must also propose a code containing the private label distributor's labeler code, for each package size and type so distributed.
Is the listing database fully public?
Mostly. All establishment registration information is available for public disclosure, and after a drug is marketed so is the information obtained under the code, listing and updating sections. Three categories are withheld unless already public, or unless confidentiality would be inconsistent with protecting public health. The basis for a determination that a drug is not subject to the new drug or biologics provisions. Inactive ingredient names under a valid confidentiality assertion. And listing information obtained under the reservation and certain listing paragraphs.